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Abstract. Aim: We investigated tissue biomarkers in non-
small cell lung cancer (NSCLC) to find indicators of brain
metastasis and peritumoral brain edema. Patients and
Methods: Fifty-two cases were studied out of which 26 had
corresponding brain metastatic tissue. Clinicopathological
characteristics of tumors were correlated with biomarkers of
cell adhesion, cell growth, cell cycle and apoptosis
regulation that were previously immunohistochemically
studied but never analyzed separately according to
histological subgroups, gender and smoking history. Results:
Increased collagen XVII in adenocarcinoma (ADC) and
increased caspase-9, CD44v6, and decreased cellular
apoptosis susceptibility protein (CAS) and Ki-67 in squamous
cell carcinoma (SCC) correlated significantly with brain
metastasis. Increased β-catenin, E-cadherin and decreased
caspase-9 expression in primary SCC, and decreased CD44v6
expression in brain metastatic SCC tissues showed a
significant correlation with the extent of peritumoral brain
edema. Positive correlation between smoking and biomarker
expression could be observed in metastatic ADCs with p16
and caspase-8, while-negative correlation was found in SCC
without brain metastasis with caspase-3, and in SCC with
brain metastasis with p27. Conclusion: Our results highlight
the importance of separate analysis of biomarker expression
in histological subtypes of NSCLC. 
Lung cancer is the leading cause of cancer-related death
worldwide. Non-small cell lung cancer (NSCLC) accounts
for more than 80% of lung cancer and it has two main
subtypes, namely adenocarcinoma (ADC) and squamous cell
carcinoma (SCC). During the last years it became clearly
evident that these two subtypes represent distinct entities
regarding not only their histological phenotypes,
immunohistochemical and molecular biological profiles, but
also their therapeutic approaches (1). About 80% of NSCLC
cases are inoperable at the time of diagnosis, with a high
frequency of hematogenous dissemination. Lung cancer is
the most common primary tumor to metastasize to the brain
and brain metastasis is one of the most important factors
influencing the quality of life in lung cancer patients (2).
Peritumoral brain edema plays a major role in determining
symptoms and prognosis, therefore, a better understanding
of mechanisms related to its evolution is highly required (3).
Great efforts have been made to predict the sites of
metastases from lung cancer. D’Amico et al. have used
molecular biologic markers and found that patients with
isolated brain relapse had significantly higher expression of
p53 and urokinase plasminogen activator (4). Li et al. have
genotyped 33 single-nucleotide polymorphisms from 13 genes
in the transforming growth factor-beta (TGF-β) signaling
pathway and evaluated their associations with brain metastasis
risk by using DNA from blood samples from 161 patients with
NSCLC. They found the GG genotype of SMAD6:
rs12913975 and TT genotype of INHBC: rs4760259 to be
associated with risk of brain metastasis (5). Recently,
associations between single-nucleotide polymorphisms in the
PI3K-PTEN-AKT-mTOR pathway and increased risk of brain
metastasis in patients with NSCLC were demonstrated by Li
and coworkers (6). Singhal et al. reviewed molecular markers
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or proteins that may have prognostic significance in early
stage NSCLC. They focused on biomarkers primarily involved
in one of three major pathways: cell-cycle regulation,
apoptosis and angiogenesis. Although no single marker has yet
been shown to be adequately indicative in predicting patients’
outcome, the markers with the strongest evidence as
independent predictors of patient’s outcome included cyclin E,
cyclin B1, p21, p27, p16, survivin, collagen XVIII and
vascular endothelial cell growth factor (7). 
We have already investigated the immunophenotypic
profile of NSCLC with and without brain metastasis using
biomarkers of cell adhesion, cell growth, cell cycle and
apoptosis regulation; the tissue microarray approach (TMA)
has also been employed (8). We could demonstrate by cluster
analysis that the brain metastatic potential of NSCLC may
be linked to the elevated levels of cyclin D1, cyclin D3, p16,
syndecan-1, p53, caspase-3, caspase-9, CD44v6 and collagen
XVII, as well as to the down-regulation of β-catenin and
cellular apoptosis susceptibility protein (CAS). In that study,
however, different subtypes of NSCLC were analyzed
collectively and, therefore, the results yielded could not be
interpreted according to the present clinical requirements. 
The aim of our present work was to separately re-evaluate
the lung ADC and SCC cases both in brain metastatic and
control groups in order to explore whether both histological
subtypes contribute equally to the observed results. Using the
histopathological results of our previous study, we
investigated, for the first time, the correlation between
clinicopathological characteristics, such as gender and
smoking history, and the expression of different tissue
biomarkers (8). We also searched for biomarkers that could
have predictive value for peritumoral brain edema. 
Materials and Methods
Case series. Altogether 78 tumor samples were studies. We have
investigated 52 primary NSCLC tissue samples including 29 SCC, 20
ADC, 2 large cell carcinomas and 1 adenosquamous carcinoma. In 26
out of 52 patients corresponding brain metastases were also studied.
All tumors were surgically-resected specimens, formalin-fixed and
paraffin-embedded tissues. Out of 26 lung cancer patients with brain
metastasis 20 had radiomorphologic (by CT or MRI) data on thickness
of peritumoral edema that scored 0-2 (0, no edema; 1, edema <10 mm;
2, edema ≥10 mm). In the other 26 patients no brain metastasis was
detected during long term follow-up (median, 88 months). Smoking
history was available in 50 cases. The clinical and histopathological
data for all cases are summarized in Table I. The tumors were classified
histologically according to the criteria of the World Health
Organization. Permission for using the archived tissue blocks was
obtained from the Regional Ethical Committee (TUKEB N˚ 106/2005).
Immunohistochemistry. In this work we have analyzed 26 previously
immunohistochemically studied markers that targeted molecules of
cellular differentiation (CK-7, pan-CK, HBME-1, TTF-1,
chromogranin-A), cell adhesion (collagen XVII, CD44v6, E-cadherin,
β-catenin, syndecan-1), cell growth (EGFR, nm23), cell cycle
regulation (Ki67, cyclin-D1, -D3, p16, p27kip1), DNA replication/repair
(topoisomerase IIα) and apoptosis regulation (bax, bcl-2, CAS, caspase-
3, -8, -9, fas-310, p53). For TMA construction and for specification of
antibodies and immunostaining conditions used see Figure 1 of
Reference 4. Semiquantitative estimations were performed by two
independent pathologists. We here present only correlations studied and
analyses conducted that have never been performed or published. 
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Table I. Patients’ characteristics.
Characteristics Lung cancer Lung cancer
with brain metastasis without brain metastasis 
(Control group)
Number of patients 26
(20 metachronous/6 synchronous) 26
Males/females 17/9 19/7
Mean age/(range) 56.8 (36-75) years 56.4 (42-72) years
Histology
Squamous cell carcinoma 14 15
Adenocarcinoma 9 11
Large cell carcinoma 2 0
Adenosquamous carcinoma 1 0
Stage (at time of primary
tumor diagnosis) IA,1; IB, 7; IIA, 1; IIB, 6; IIIA, 3; IIIB, 2; IV,6 IA, 5; IB, 13; IIA, 2;  IIB, 4; IIIA, 2
Extent of peritumoral brain edema no edema: 4
(available in 20 cases) <10 mm, 10
≥10 mm, 6
Smoking history non-smoker, 1 non-smoker, 1
(available in 50 cases) ex-smoker, 12 ex-smoker, 5
current smoker, 11 current smoker, 20
Statistical analysis. Statistical analysis was performed using the
GraphPad Prism 5 software (GraphPad Software Inc., San Diego,
CA, USA) for the Mann-Whitney U-test and Spearman non-
parametric correlation, while the SPSS 17.0 software (SPSS Inc.,
Chicago, IL, USA) was used for logistic regression analysis. The
Mann-Whitney U-test was used to compare immunohistochemical
reactions of protein markers in the different groups. The Spearman
non-parametric correlation was used to investigate co-expressions
of candidate proteins and associations between these protein
markers and gender or smoking habits. Logistic regression method
was used to predict appearance of metastasis and edema by protein
expressions as well. 
Results
Two large cell carcinoma samples and one squamous cell
carcinoma sample showed markedly different protein
expression profiles either from ADCs or from SCCs,
therefore, they were excluded from statistical analyses. 
Regression analysis for predicting brain metastasis showed
that increased collagen XVII (p=0.0110) in ADC, increased
caspase-9 (p=0.0080), CD44v6 (p=0.0310), and decreased
CAS (p=0.029) and Ki67 (p=0.0319) in SCC correlated
significantly with brain metastasis (Table II) (Figure 1). 
During the metastatic progression in the ADC subgroup,
significant marker loss of β-catenin (p=0.0370) was
observed, while the E-cadherin and bax marker loss were
nearly significant (p=0.054 and p=0.059, respectively).
When examining marker gain in the ADC subgroup,
significant changes were found in p16, topoIIα, syndecan-1,
cyclin D1 and CAS expression, while a positive trend was
observed regarding cyclin D3 and Ki67 expression (p=0.066,
and p=0.083, respectively) (Table II). 
The correlation between smoking rate and biomarker
expression could be observed in certain cases (Table III). A
significant positive correlation was found in the metastatic
ADC subgroup with p16 (p=0.024) and caspase-8 (p=0.045)
expression. In SCC a negative correlation was found in the
non-metastasizing subgroup with caspase-3 (p=0.039)
expression. In primary SCC with brain metastasis there was
a negative correlation between smoking and p27 expression
(p=0.038). It is, however, of importance that apart from one
case all patients were ex- or present smokers.
The correlation between female gender and biomarker
expression was also examined. In ADC, decreased cyclin-D1
showed a significant correlation with female gender, but only
in the non-metastasizing primary tumor group (p=0.016),
while in SCC we found no correlation between biomarker
expression and gender (Table III). 
When we studied markers’ characteristic for wider
peritumoral brain edema, we found no significant
correlations either in primary or in metastatic ADC. In
primary SCC, however, increased β-catenin (p=0.0259) and
E-cadherin (p=0.0259), as well as decreased caspase-9
(p=0.0373) expression showed a significant correlation. In
brain metastatic SCC tissues decreased CD44v6 expression
showed highly significant correlation with the extent of
peritumoral brain edema (p=0.0021) (Table III). 
Discussion
Early brain metastasis or cerebral relapse remains an
important cause of morbidity and mortality in NSCLC, with
the mechanisms of brain metastatic process remaining poorly
understood. In breast cancer for example, certain cell-surface
markers, such as nm23 and CD44 are indicators and/or
predictors of distant metastasis (9). Similarly, breast cancer
cells that are Her2-positive are more likely to metastasis to
the brain (10).
Our group has already demonstrated that brain metastatic
potential of NSCLC may be linked to the elevated levels of
CD44v6 and caspase-9, and decreased level of CAS
expression. In that work separate analysis regarding
histologic subtypes of NSCLC has not been carried out,
therefore, this is the first time that we could demonstrate that
the previously observed correlation was mainly related to the
SCC subgroup. Recently, an interesting work demonstrated
effects of different sequences of pulmonary artery and vein
ligations during pulmonary lobectomy on CD44v6 mRNA
expression and blood micrometastasis of NSCLC (11). In the
study of Afify et al. CD44v6 expression correlated
significantly with lymph node metastases and tumor size in
lung adenocarcinoma (12). In squamous cell carcinoma of
the esophagus CD44v6 protein expression was found to
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Figure 1. Collagen XVII expression in lung SCC (hematoxylin eosin
staining ×200). Collagen XVII expression is diffusely-expressed in the
cytoplasm of cancer cells, but is undetectable in adjacent stromal cells.
correlate with the infiltration and the metastases (13).
Peritumoral brain edema plays a crucial role in
deterioration of the quality of life in patients with metastatic
lung cancer; however, the exact pathomechanisms related to
its development is poorly understood. Sawada et al.
evaluated aquaporin-4 protein expression in different brain
tumors by immunohistochemistry but only glial tumor cells
exhibited a positive reaction for aquaporin-4 (14). Recently,
higher transcript and protein levels of aquaporin-4 in well-
differentiated lung adenocarcinomas were described and an
association with a more favorable prognosis was observed
(15). In our work, decreased caspase-9 and increased β-
catenin and E-cadherin expression were markers for wider
peritumoral brain edema in SCC. In brain metastatic tissues
in ADC no such marker was identified, while in SCC low
CD44v6 expression showed a significant correlation. 
It might be of interest that in the SCC subgroup markers
with positive correlation for brain metastasis showed a
negative correlation for the extent of peritumoral brain
edema, such as CD44v6 and caspase-9 expression. Further
studies are required to elucidate the relevance of this
observation.
Regarding previously studied biomarkers, we demonstrated
for the first time that in ADC increased cyclin-D1, p27 and
EGFR expression showed a significant correlation, while in
the SCC subgroup increase in topo-II α and decrease in
caspase-9 expression proved to correlate significantly with
smoking, although the proportion of never smokers in both
ADC and SCC subgroups was very low. Nevertheless, the
observed correlation between smoking and decreased caspase-
9 expression might be in accordance with the findings of Chen
et al. who demonstrated that cigarette smoking suppressed the
activity of caspase-3, which could have led to the proliferation
and growth of lung cancer cells in human cell lines (16). 
There are hardly any data on gender differences regarding
the studied biomarkers. In our present work, only the
decreased cyclin D1 levels had significant correlation with
female gender in ADC, whereas decreased CD44v6 was
nearly significant (p=0.0528). On the contrary, increased
p27, caspase-3 and caspase-9 expression in SCCs all showed
a positive correlation with a high level of significance.
Interestingly, the observed decreased CD44v6 expression in
our female ADC patients is the opposite of what Vermeulen
et al. reported recently in breast cancer patients, where
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Table II. Significant differences in biomarker expression in ADC and SCC (p<0.05 in all cases; bold when p≤0.01). 
ADC SCC
Lung cancer with brain metastasis compared to lung cancer without brain metastasis + collagen XVII + caspase-9,
+ CD44v6
– CAS,
– Ki67
Marker gain in brain metastasis p16, topoIIα, CAS, syndecan-1, cyclin D1 caspase-3
Marker loss in brain metastasis β-catenin
+: Positive correlation; –: negative correlation. ADC: adenocarcinoma; SCC: squamous cell carcinoma; CAS: cellular apoptosis susceptibility protein.
Table III. Biomarker expression differences in ADC and SCC according to gender, smoking history and peritumoral brain edema (p<0.05 in all
cases).
ADC SCC
Primary tumor Primary tumor Brain Primary tumor Primary tumor Brain 
non-metastatic group with brain metastasis metastasis non-metastatic group with brain metastasis metastasis
Smoking + p16 
+ caspase 8
– caspase 3 – p27
Female gender
- cyclin D1
Peritumoral edema + β-catenin 
+ E-cadherin
– caspase-9 – CD44v6
+: Positive correlation; –: negative correlation. ADC: adenocarcinoma; SCC: squamous cell carcinoma.
CD44v6 expression was increased in females when
compared to male breast cancer patients (17). 
Molecular markers that are of predictive value for brain
metastasis might help clinicians to change follow-up and
treatment strategies or to diagnose brain metastasis early
enough for effective therapy. The present study highlights the
importance of epigenetic factors, such as smoking and
gender differences that might influence the expression of
biomarkers playing a role in the metastatic process. Our
results may facilitate further studies aiming to select NSCLC
patients with high risk for brain metastasis who might benefit
from prophylactic cranial irradiation. A better understanding
of the formation of peritumoral edema in lung cancer brain
metastasis might facilitate the development of novel
therapeutic strategies. 
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